APPENDIX 6: MIRERC Continuing Review Form

F-1-39-5

PROTOCOL/PROPOSAL NO.	MIRERC NO.
STUDY TITLE:	
NAME OF CORRESPONDING PRINCIPAL INVESTIGATOR:	MIRERC APPROVED SITES:
DATE OF INITIAL APPROVAL:	DATE OF LAST ANNUAL RENEWAL:
ACTION REQUESTED: □ Renew – New subjects enrollment to continue □ Renew – Enrolled subjects follow up only	TRIAL DURATION (MONTHS): Recruitment Duration Trial Duration
SUMMARY OF STUDY SUBJECTS (MIRERC APPROVED SITES):Enrolment ceiling set by MIRERC (Target Number during time of approval)New subjects enrolled since initial approval / last annual renewalTotal subjects enrolled since study started.	HAS ANY SUBJECT WITHDRAWN FROM THIS STUDY SINCE THE LAST MIRERC APPROVAL? NO YES (Discuss in the attached narrative)
ENROLLMENT EXCLUSIONS: NONE MALE FEMALE	IMPAIRED SUBJECTS: NONE PHYSICALLY COGNITIVELY BOTH
IONIZING RADIATION USE (X-RAYS, RADIOISOTOPES, ETC) None Medically indicated only	INVESTIGATIONAL NEW DRUG / DEVICE NO IND IDE FDA Number
HAVE THERE BEEN ANY CHANGES IN THE SUBJECT POPULATION, RECRUITMENT OR SELECTION CRITERIA SINCE THE LAST REVIEW? NO YES (Explain changes in attached narrative)	HAS ANY INFORMATION APPEARED IN THE LITERATURE, OR EVOLVED FROM THIS OR SIMILAR RESEARCH THAT MIGHT AFFECT THE MIRERC'S EVALUATION OF THE RISKS / BENEFITS ANALYSIS OF HUMAN SUBJECTS INVOLVED IN THIS STUDY? NO YES (Discuss in the attached narrative)
HAVE THERE BEEN ANY CHANGES IN THE INFORMED CONSENT PROCESS OR DOCUMENTATION SINCE THE LAST REVIEW? NO YES (Explain changes in attached narrative)	HAVE ANY CO- / SITE INVESTIGATORS BEEN ADDED OR REMOVED SINCE THE LAST REVIEW? NO YES (Identify all changes in attached narrative)
HAVE ANY INVESTIGATOR DEVELOPED EQUITY OR CONSULTATIVE RELATIONSHIP WITH A SOURCE RELATED TO THIS STUDY WHICH MIGHT BE CONSIDERED A CONFLICT OF INTEREST? NO YES (Append a statement of disclosure)	HAVE ANY NEW COLLABORATING SITES (INSTITUTIONS) BEEN ADDED OR REMOVED SINCE THE LAST REVIEW? NO Service No Service States of the service of
HAVE THERE BEEN ANY OTHER AMENDMENTS SINCE THE LAST REVIEW? NO YES (Explain changes in attached narrative)	HAVE ANY UNEXPECTED COMPLICATIONS OR SIDE EFFECTS BEEN NOTED SINCE LAST REVIEW? NO YES (Discuss in the attached narrative) NA *
SIGNATURE:	

* For non-clinical studies

It is compulsory to renew your ethical approval every year unless otherwise specified. Please note that your ethical approval is valid for only a specified time based on the risk benefit assessment by the MIRERC. This time period is specified in the approval letter by MIRERC. To avoid delay, please submit your renewal application **at least two months** in advance before expiry. If your ethical approval is not renewed you are not to continue the study until approval is obtained

(CORRESPONDING PRINCIPAL INVESTIGATOR)

(DATE)

* For non-clinical studies

It is compulsory to renew your ethical approval every year unless otherwise specified. Please note that your ethical approval is valid for only a specified time based on the risk benefit assessment by the MIRERC. This time period is specified in the approval letter by MIRERC. To avoid delay, please submit your renewal application **at least two months** in advance before expiry. If your ethical approval is not renewed you are not to continue the study until approval is obtained